Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.09 USD
Change Today 0.00 / 0.00%
Volume 3.0K
INNV On Other Exchanges
As of 8:10 PM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

innovus pharmaceuticals inc (INNV) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/29/14 - $0.42
52 Week Low
09/29/15 - $0.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

innovus pharmaceuticals inc (INNV) Related Businessweek News

No Related Businessweek News Found

innovus pharmaceuticals inc (INNV) Details

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription pharmaceutical and consumer health products in the United States and internationally. The company’s products include Zestra, a non-medicated, patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity low osmolality water-based lubricant; and Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health. It has an agreement with Laboratorios Q Pharma to distribute and commercialize Androferti, a natural supplement that supports male reproductive health and sperm quality; and develops Fluticare, a nasal spray in the form of fluticasone propionate, which is in FDA approval stage. The company markets its products directly or through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is headquartered in San Diego, California.

3 Employees
Last Reported Date: 03/31/15

innovus pharmaceuticals inc (INNV) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $281.3K
Compensation as of Fiscal Year 2014.

innovus pharmaceuticals inc (INNV) Key Developments

Innovus Pharmaceuticals, Inc. Enters into Marketing and Distribution Agreement with Khandelwal Laboratories

Innovus Pharmaceuticals, Inc. announced it has entered into an marketing and distribution agreement with Khandelwal Laboratories under which Innovus Pharma has granted to KLab an exclusive ten-year license and distribution rights to market and sell Innovus Pharma’s products including Zestra® to increase Female Sexual Arousal, Desire and Satisfaction, EjectDelay® for treating premature ejaculation, Sensum+® to increase penile sensitivity and Zestra Glide® the high viscosity water based lubricant. If KLabs exceeds its minimum yearly orders, the agreement has two five-year term extensions. This deal has been facilitated by Nortons (UK). Under the agreement, the minimum orders for the first term of the agreement are over $2.6 million.

Innovus Pharmaceutical Enters into an Exclusive License Agreement with Elis Pharmaceuticals

On July 4, 2015, Innovus Pharmaceuticals, Inc. announced that it had entered into an exclusive license agreement with Elis Pharmaceuticals, an emirates company, under which Innovus Pharma granted to Elis an exclusive license to market and sell to market and sell Innovus Pharma's topical product Zestra for female sexual dysfunction, treatment for premature ejaculation EjectDelay, its product Sensum+ to increase penile sensitivity, Vesele to increase sexual and cognitive health and Zestra Glide, its high viscosity water-based lubricant in Turkey and select African and gulf countries. Under the agreement, Innovus Pharma is eligible to receive up to $35.5 million in sales milestone payments plus an agreed-upon transfer price.

Innovus Pharmaceuticals, Inc. Announces Executive Changes

Innovus Pharmaceuticals, Inc. announced that Lynnette Dillen, Executive Vice President and Chief Financial Officer of the company has decided to leave the company for another opportunity in the biotechnology industry. Ms Dillen is expected to remain in her current role at Innovus effective no later than July 16, 2015. Following Ms Dillen's departure, Mr. Reuven Rubinson Vice President of Finance will assume leadership of the company's accounting and finance functions. Reuven is a senior hands-on financial executive with over 30 years of proven leadership and demonstrated management skills as Chief Financial Officer of both public and private companies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNV:US $0.09 USD 0.00

INNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INNV.
View Industry Companies

Industry Analysis


Industry Average

Valuation INNV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOVUS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at